ENTA — Enanta Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $281.80m
- -$53.93m
- $79.20m
- 26
- 19
- 68
- 31
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 205 | 122 | 97.1 | 86.2 | 79.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 168 | 164 | 207 | 210 | 216 |
Operating Profit | 36.7 | -41.6 | -110 | -124 | -137 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 45.6 | -35 | -108 | -122 | -131 |
Provision for Income Taxes | |||||
Net Income After Taxes | 46.4 | -36.2 | -79 | -122 | -134 |
Net Income Before Extraordinary Items | |||||
Net Income | 46.4 | -36.2 | -79 | -122 | -134 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 46.4 | -36.2 | -79 | -122 | -134 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.21 | -1.81 | -3.92 | -5.91 | -6.38 |